Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This investigational autologous cell therapy consists of mesenchymal stromal cells (MSCs) derived from the patient's own bone marrow, developed by the Clínica Universidad de Navarra and the Universidad de Navarra. It is specifically designed for the treatment of idiopathic pulmonary fibrosis (IPF). The therapy is administered via a single endobronchial infusion. The mechanism of action involves the immunomodulatory and anti-inflammatory properties of MSCs, which are thought to migrate to sites of lung injury and secrete paracrine factors that reduce alveolar inflammation and inhibit fibrotic processes. A Phase I dose-escalation trial has evaluated the safety and feasibility of this approach in patients with mild-to-moderate IPF.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous bone marrow-derived mesenchymal stem cells (Clínica Universidad de Navarra).